

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3950722

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ONYX PHARMACEUTICALS INC.	03/16/2016
RECEIVING PARTY DATA		
Name:	BTG INTERNATIONAL LIMITED	
Street Address:	5 FLEET PLACE	
City:	LONDON	
State/Country:	ENGLAND	
Postal Code:	EC4M 7RD	
PROPERTY NUMBERS Total: 2		
	Property Type	Number
	Application Number:	13996618
	Patent Number:	8809526
CORRESPONDENCE DATA		
Fax Number:	(216)621-4072	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	216-621-2234	
Email:	tballou@tarolli.com	
Correspondent Name:	TAROLLI, SUNDHEIM, COVELL & TUMMINO LLP	
Address Line 1:	1300 EAST NINTH STREET, SUITE 1700	
Address Line 4:	CLEVELAND, OHIO 44114	
ATTORNEY DOCKET NUMBER:	ME-021904 & 022377 US PCT	
NAME OF SUBMITTER:	RAYMOND N. RUSSELL	
SIGNATURE:	/Raymond N. Russell/	
DATE SIGNED:	07/07/2016	
Total Attachments: 8		
source=ME-assignment#page1.tif		
source=ME-assignment#page2.tif		
source=ME-assignment#page3.tif		
source=ME-assignment#page4.tif		
source=ME-assignment#page5.tif		

source=ME-assignment#page6.tif

source=ME-assignment#page7.tif

source=ME-assignment#page8.tif

DATED March 16, 2016

ONYX PHARMACEUTICALS INC

and

BTG INTERNATIONAL LIMITED

ASSIGNMENT of PATENTS

[illegible]

1.

This Assignment (this "Assignment") is made as a deed on the 16th day of March, 2016

BETWEEN:

- (1) **ONYX PHARMACEUTICALS INC.**, a Delaware corporation with a place of business at 249 E. Grand Avenue, South San Francisco, CA 94080 ("ONYX")
- (2) **BTG INTERNATIONAL LIMITED** a company whose registration number is 2664412 and whose registered office is at 5 Fleet Place, London EC4M 7RD ("BTG").

Whereas:-

- A. Onyx is the proprietor and/or beneficial owner of the granted patents and patent applications, details of which are set out in Schedule 1 to this Assignment, (all such granted patents, patent applications are herein together called the "IPR").

Now it is hereby agreed as follows:-

1. Definitions

"Effective Date" shall mean the date of this Agreement;

2. ONYX hereby (with effect from the Effective Date) assigns to BTG all its right, title and interest in and to the IPR including:

2.1 the right to claim priority from and to prosecute and obtain grant of patent;

2.2 the right to file divisional applications or continuation applications based thereon and to prosecute and obtain grant of patent on each and any such divisional application;

2.3 in respect of each and any invention disclosed in the IPR, the right to file an application, claim priority from such application, and prosecute and obtain grant

of patent or similar protection in or in respect of any country or territory in the world;

2.4 the right to extend to or register in, or in respect of, any country or territory in the world each and any of the IPR, and each and any of the applications comprised in the IPR filed as aforesaid, and to extend to or register in or in respect of any country or territory in the world any patent or like protection granted on any of such applications comprised in the IPR;

2.5 the absolute entitlement to any patents granted pursuant to any of the applications comprised in the IPR filed as aforesaid; and

2.6 the right to bring, make, oppose, defend, appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of any of the IPR or any patents granted on any of the applications comprised in the IPR filed as aforesaid, whether occurring before, on or after the date of this assignment.

3. Further Assurances by ONYX

3.1 ONYX shall, at the reasonable request and cost of BTG, execute and do all such documents, facts and things as may be necessary on the part of ONYX to give effect to the terms of this Agreement.

3.2 ONYX hereby confirms to BTG that it has the legal authority and right to assign the IPR under this Agreement.

4. Warranties

4.1 ONYX warrants that

(a) all application fees in relation to the IPR have been paid; and

(b) it has not assigned or licensed any of the rights under the IPR to any other party.

5. Entire Agreement

5.1 This Agreement constitutes the whole agreement between the parties and supersedes all previous agreements between the parties relating to its subject matter.

5.2 Each party acknowledges that, in entering into this agreement, it has not relied on, and shall have no right or remedy in respect of, any statement, representation, assurance or warranty (whether made negligently or innocently) other than as expressly set out in this agreement.

5.3 Nothing in this Agreement shall limit or exclude any liability for fraud.

6. Variation

No variation of this agreement shall be effective unless it is in writing and signed by the parties (or their authorised representatives).

7. Severance

7.1 If any court or competent authority finds that any provision of this agreement (or part of any provision) is invalid, illegal or unenforceable, that provision or part-provision shall, to the extent required, be deemed to be deleted, and the validity and enforceability of the other provisions of this agreement shall not be affected.

7.2 If any invalid, unenforceable or illegal provision of this agreement would be valid, enforceable and legal if some part of it were deleted, the parties shall negotiate in good faith to amend such provision such that, as amended, it is legal, valid and

enforceable, and, to the greatest extent possible, achieves the parties' original commercial intention.

8. Counterparts

This Assignment may be executed in any number of counterparts, each of which when executed and delivered shall constitute an original of this agreement, but all the counterparts shall together constitute the same agreement. No counterpart shall be effective until each party has executed at least one counterpart.

9. Third Party Rights; Announcements

Save in relation to the rights of a Licensee under its respective Licence:

9.1 no person other than a party to this agreement shall have any rights to enforce any term of this agreement; and

9.2 the contents of this Agreement shall be considered confidential information and neither party shall make any public announcement relating to this Agreement without the prior written consent of the other party.

10. Notices

10.1 Any notice or other communication required to be given under this agreement shall be in writing and shall be delivered personally, or sent by pre-paid first-class post or recorded delivery or by commercial courier, to each party required to receive the notice or communication as set out below:

ONYX: c/o Corporate Secretary, Amgen Inc., One Amgen Center Drive,
Thousand Oaks, California 91320

BTG: Director of Intellectual Property, BTG International Limited, 5 Fleet
Place, London EC4M 7RD

or as otherwise specified by the relevant party by notice in writing to each other
party.

10.2 Any notice or other communication shall be deemed to have been duly received:

10.2.1 if delivered personally, when left at the address and for the contact
referred to in this clause;

10.2.2 if sent by pre-paid first-class post or recorded delivery, at 9.00 am on the
third Business Day after posting; or

10.2.3 if delivered by commercial courier, on the date and at the time that the
courier's delivery receipt is signed.

10.3 A notice or other communication required to be given under this agreement shall
not be validly given if sent by e-mail.

10.4 The provisions of this clause shall not apply to the service of any proceedings or
other documents in any legal action.

11. This Agreement shall be read and construed in accordance with and governed by
English law and the parties submit to the exclusive jurisdiction of the English Courts.

IN WITNESS whereof this document has been executed and delivered as a deed on the date
first written above.

SCHEDULE 1

The IPR

FBI NO.	COUNTRY	APPLICATION NO.	DATE FILED	PUBLICATION NO.	ISSUE DATE	PATENT NO.	EXPIRATION DATE	STATUS
S01319EP01	European Patent Office	11809866.2	15-Jul-2011	2595966			15-Jul-2031	Pending
S01319US01	United States of America	61/399,861	19-Jul-2010				19-Jul-2031	Expired
S01319US02	United States of America	13/810,783	15-Jul-2011	2013-0211082	19-Aug-2014	6,809,376	15-Jul-2031	Issued
S01319WC01	PCT	PCT/US2011/001235	15-Jul-2011	WO12/011939			15-Jul-2031	NP Entered
S01320EP01	European Patent Office	11850150.1	19-Dec-2011	2655398			19-Dec-2031	Pending
S01320US01	United States of America	61/453,952	22-Dec-2010				22-Dec-2031	Expired
S01320US02	United States of America	13/995,618	19-Dec-2011	2013-0345423			19-Dec-2031	Pending
S01320WC01	PCT	PCT/US2011/065752	19-Dec-2011	WO12/087888			19-Dec-2031	NP Entered

12/19/2016

Filed

Executed by)
ONYX PHARMACEUTICALS INC
in a manner legally binding upon it)

Stuart Z Watt

Director/Authorised Signatory
Date:



Executed by)
BTG INTERNATIONAL LIMITED
in a manner legally binding upon it)

Paul Musenden

Director:
Date:

Paul Musenden

Director: **PAUL MUSSENDEN**
Date: